2. UroToday Home
  3. Conference Highlights
  4. ESOU 2019

ESOU 2019 Prostate Cancer

ESOU 2019: Treatment of Gleason 3+4 in a Multidisciplinary Scenario: Surgery

Prague, Czech Republic (UroToday.com) Dr. Henk Van Der Poel was tasked with making the case for surgical treatment of Gleason 3+4 prostate cancer.

ESOU 2019: Treatment of Gleason 3+4 in a Multidisciplinary Scenario: Hypofractionation Radiation Therapy

Prague, Czech Republic (UroToday.com) As part of the multidisciplinary prostate cancer session at ESOU 2019 discussing treatment options for men with Gleason 3+4 disease, Dr. Alberto Bossi presented his thoughts on hypofractionated radiation therapy.

Dr. Bossi started with highlighting for the urologists in the room the dose and fractionation schedule for conventional, moderate and extreme treatment plans:

ESOU 2019: Treatment of Gleason 3+4 in a Multidisciplinary Scenario: Focal Therapy

Prague, Czech Republic (UroToday.com) Dr. Clement Orczyk made the case for considering focal therapy among men with Gleason 3+4 disease at today’s multidisciplinary prostate cancer session at ESOU 2019.

Dr. Orczyk started by highlighting that Gleason 3+4 disease is truly a multidisciplinary process, even in the focal therapy platform where patients may be candidates for cryosurgery or high-intensity focused ultrasound (HIFU). Dr. Orczyk considers a “target lesion” as having to have the following criteria:

ESOU 2019: Treatment of Gleason 3+4 in a Multidisciplinary Scenario: Active Surveillance

Prague, Czech Republic (UroToday.com) As part of the ESOU 2019 prostate cancer session there was a discussion regarding the appropriate treatment of Gleason 3+4 disease. Dr. Monique Roobol discussed the possible utilization of active surveillance for these patients.

ESOU 2019: An Update in Prostate Cancer Prevention

Prague, Czech Republic (UroToday.com) Dr. Sabrina Brookman-May gave an overview of several modalities of prostate cancer prevention.
Several lifestyle factors have been discussed as potential parameters with an impact on prostate cancer risk and prognosis. These have largely been developed based on two robust and impactful recent systematic reviews by the ESOU1,2

ESOU 2019: Treating Primary Metastatic Disease, a Case for Surgery Plus or Minus Radiotherapy

Prague, Czech Republic (UroToday.com) In this session, Dr. Heidenreich presentes his case for the role of cytoreductive prostatectomy in the setting of primary hormone-naïve metastatic prostate cancer.

ESOU 2019: Symptomatic Metastatic Castration-sensitive Hormone-naïve Prostate Cancer: Evidence from CHAARTED, LATITUDE, and STAMPEDE

Prague, Czech Republic (UroToday.com) Dr. Joaquim Bellmunt gave an overview of the management of mHSPC (metastatic hormone-sensitive prostate cancer), based on current evidence to date. In 2019, management of mHSPC is a chess game – we have a lot of moves/options, we want to use as many as possible, but it requires a strategy from the very first move (mHSPC).
Page 1 of 5
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe